View Document Preview and Link Document Date: 2012-12-09 11:48:23 Open Document File Size: 71,60 KB Share Result on Facebook
City Dysport / Paris / / Company AEs / Active Biotech AB / Ipsen / Biotech Active Biotech AB / Ipsen Media Didier Véron / / Country France / United States / Sweden / / Currency EUR / / / / IndustryTerm treatment of multiple sclerosis / treatment of prostate cancer / biotechnology / treatment of renal cell cancer / clinical protocol / healthcare / pharmaceutical / / MarketIndex SBF 120 / / MedicalCondition cancer / disease / fatigue / multiple sclerosis / diseases / carcinomas / resistant prostate cancer / prostate cancer / Lupus / hemophilia / inflammatory / disorders / Systemic Sclerosis / / MedicalTreatment clinical protocol / chemotherapy / / Organization American Society / / Person Marc de Garidel / Active Biotech / Tomas Leanderson / / / Position Investor Relations Manager / leader / forward to the continued development / Chairman and Chief Executive Officer / President & CEO / Vice President / Public Affairs and Corporate Communications / Vice President / Corporate Finance / / PublishedMedium Journal of Clinical Oncology / / Technology clinical protocol / biotechnology / chemotherapy / / URL www.ipsen.com / www.activebiotech.com / / SocialTag 
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer